This landmark acquisition marks Cormica’s first entry into the German market, a key milestone in its strategy to expand its European footprint. The move underlines Cormica’s commitment to becoming a leading operator in high-growth European markets, with plans to explore additional opportunities for expansion in Germany.
Founded in 2001, Zwisler Laboratorium operates from a modern facility in southern Germany and delivers tailored services to pharmaceutical, biotech, packaging and medical device industries across Europe. The laboratory specialises in in-vitro pyrogen test, reprocessing (instruction for use) validation, environmental monitoring, microbiological integrity tests, and bespoke consulting services to support clients in meeting stringent regulatory requirements. It has also developed cutting-edge in-vitro testing options to reduce in-vivo testing, further advancing its commitment to innovation.
Cormica, backed by Limerston Capital, operates leading laboratory facilities in the UK and the US, offering a broad spectrum of testing services including medical device proof-of-concept testing, in-vitro validation, pharmaceutical and device stability studies and batch release testing. Its services extend to GxP compliance, biocompatibility, sterility, broader microbiological testing, and physical performance testing, ensuring thorough support for clients.
With a rapidly growing reputation as a global leader, Cormica is committed to helping life science manufacturers bring lifesaving medical technologies to market more quickly, more safely, and more efficiently.
The acquisition of Zwisler builds on this mission, bringing German-based microbiological expertise into Cormica’s portfolio and providing clients with access to an expanded range of services. The move strengthens Cormica’s ability to support its customers in navigating the complex regulatory environments of Europe and beyond.
Mark Hammond, CEO of Cormica Group, commented: “This acquisition is a significant milestone for Cormica Group. Germany is a critical market for life sciences, and establishing a foothold here has been a long-term priority for us.
“Zwisler Laboratorium has an exceptional reputation for quality and innovation, and we are pleased to welcome its talented team into the Cormica family. This is just the beginning of our journey in Germany, and we look forward to building on this foundation to expand further in the region.”
Dr Zwisler, former owner of Zwisler Laboratorium, said: “Joining Cormica Group is an exciting new chapter for Zwisler Laboratorium with a great potential for the future. Our shared commitment to excellence and innovation makes this a natural partnership.
“With Cormica’s global reach and resources, we can expand our capabilities and continue delivering the high-quality services our clients rely on. I am confident this collaboration will unlock new opportunities for growth, both for our team and for our customers.”
Jane Grewar, Senior Operating Partner at Limerston Capital, added: “We are pleased to support Zwisler Laboratorium in its next phase of growth as part of the Cormica family. Our shared commitment to ensuring that safe, effective devices reach patients in the most timely and efficient way possible lies at the heart of this acquisition. Together, we can further enhance our ability to deliver innovative testing solutions that help our clients navigate regulatory challenges, ultimately accelerating the delivery of life-saving technologies to those who need them most.
“Germany is a key growth area for Cormica and this is an exciting first foothold in the market.”
For further information about Cormica Group, visit
